It is designed to mimic the eyes natural capability to change focus.

Abbott’s news releases and other details can be found on the company’s Site at.. Abbott Completes Visiogen Acquisition Abbott has completed its acquisition of privately held eye treatment firm Visiogen, expanding the business’s vision care business with a next-generation accommodating intraocular lens technology to handle presbyopia for cataract sufferers. It is designed to mimic the eye’s natural capability to change focus , delivering improved vision at all distances, removing the need for contacts or glasses potentially, reducing glare and nighttime halos, and improving contrast sensitivity. Abbott’s $400 million cash buy of Visiogen boosts the company’s presence in the vision care segment, in February 2009 using its acquisition of Advanced Medical Optics which it entered.Food and Drug Administration that could have resulted in the failures in a few of the devices. After a death of an individual in 2004, Guidant delivered a product update to advise doctors that the yellow warning display screen warned of a potentially serious problem in the device in 2005. This change designed to decrease the ongoing health risk had not been reported as product correction but as product update. Guidant broke regulations by not really notifying the FDA about the change within 10 days.